NCT01844401View on ClinicalTrials.gov

Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

October 31, 2013

Conditions
Asthma
Interventions
DRUG

Albuterol Spiromax®

Albuterol Spiromax® 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose

DRUG

ProAir® HFA

ProAir® HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose

Trial Locations (1)

Unknown

Teva Investigational Site 10538, Costa Mesa

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT01844401 - Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma | Biotech Hunter | Biotech Hunter